Treatment of social anxiety disorder

Comparing the effectiveness of Paroxetine, Attention Modification Program and combination of both on improving social anxiety symptoms

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT201102035750N1

Enrollment

Registered

2012-03-10

Start date

2010-09-23

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

social phobia. Social phobias

Interventions

Intervention 1: Attention modification group: Participants will complete probe-detection task. This task consists of paired words appearing on computer screen in a short time. One word is emotionally

Treatment - Other

Treatment - Drugs

Attention modification group: Participants will complete probe-detection task. This task consists of paired words appearing on computer screen in a short time. One word is emotionally negative and is

Pharmachotherapy group: participants will receive standard dosage of paroxetine orally (20mg to 50mg, daily).

Combined group: Participants in combined group will receive both pharmachotherapy and attention modification program.

Eligibility

Sex/Gender

All

Age

18 Years to 50 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: Not being under pharmachotherapy before research; Not receiving psychotherapy before research; Having social anxiety disorder diagnosis according DSM-IV criteria; Having informed consent; 18 to 50 years old; At least guidance level education. Exclusion criteria: Having psychotic signs and symptoms; Substance abuse; Diagnosis of comorbid axis I disorders in DSM-IV; Suicidal ideation; Axis II diagnosis in DSM-IV.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Social phobia. Timepoint: before and after intervention with 2 months interval. Method of measurement: Social Phobia Inventory(SPIN).	—

Secondary

Measure	Time frame
Depression. Timepoint: before and after intervention with 2 months interval. Method of measurement: Beck Depression Inventory(BDI-II).;Anxiety. Timepoint: before and after intervention with 2 months interval. Method of measurement: Beck Anxiety Inventory(BAI).;General health. Timepoint: before and after intervention with 2 months interval. Method of measurement: General Health Questionnaire(GHQ).;Function. Timepoint: before and after intervention with 2 months interval. Method of measurement: Sheehan Disability Scale(SDS).	—

Measure

Time frame

Depression. Timepoint: before and after intervention with 2 months interval. Method of measurement: Beck Depression Inventory(BDI-II).;Anxiety. Timepoint: before and after intervention with 2 months interval. Method of measurement: Beck Anxiety Inventory(BAI).;General health. Timepoint: before and after intervention with 2 months interval. Method of measurement: General Health Questionnaire(GHQ).;Function. Timepoint: before and after intervention with 2 months interval. Method of measurement: Sheehan Disability Scale(SDS).

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactHosein Khedmatgozar

Tehran university of medical sciences

khedmatgozar@yahoo.com+98 21 6655 1655

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026